Aktis Oncology, Inc.

Healthcare · Biotechnology · United States

Last price 15.93 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 886.02M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225A...